#Opdivo

FDA Approves Opdivo for Small Cell Lung Cancer

Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.

Can a person’s immune system help prevent two types of non-small-cell lung cancer? Here’s how Robert Keith, MD, hopes to find out.

About 1 in 1,000 pregnant women is diagnosed with cancer. Do newer treatments, such as immunotherapy, work in this group of patients?

“It is a really important development for our patients."

An intravenous infusion of two immunotherapy drugs, Opdualag blocks activity of the proteins LAG-3 and PD-1.

Neoadjuvant Opdivo plus chemotherapy improved outcomes for people with operable non-small-cell lung cancer.

Bill Evans, a melanoma survivor, turns his love of cycling into a community building and fundraising effort.

A combination of two immunotherapy drugs showed efficacy in the treatment of advanced melanoma in a phase 3 clinical trial.

A unique analysis measures treatment-free survival after immunotherapy in patients with advanced renal cell carcinoma.

Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.

People diagnosed with advanced melanoma may soon have a new treatment option that combines two immunotherapy drugs.

More people treated with Opdivo plus Yervoy reached the 6.5-year survival mark than those treated with either drug alone.

Checkpoint inhibitor doubled disease-free survival time after surgery.